AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04483115 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tablets; Oral; Single dose
Study NCT03518151 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham comparator
Description: The control condition is provision of a limited range of fresh fruit and vegetables, all placed at the back of the store, frozen vegetables in a middle aisle and confectionery sold at checkouts.
Study NCT04089358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT04089358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials
Study NCT04089358 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FitBit
Description: Wear a Fitbit
Study NCT04089358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FitBit
Description: Wear a Fitbit
Study NCT04089358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Goal Setting
Description: Set goals
Study NCT04089358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: Receive text message about goal setting
Study NCT04089358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Follow Instagram group
Study NCT04089358 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-Based Intervention
Description: Receive phone call about goal setting
Study NCT00829998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg Capsules
Description: 1 x 10 mg, single-dose fasting
Study NCT00829998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sonata® 10 mg Capsules
Description: 1 x 10 mg, single-dose fasting
Study NCT04548011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture treatment strategies in this study are based on traditional Chinese medicine theory and opinions from the acupuncture experts. The acupoints are bilateral Zhongwan（CV12）, Tianshu（ST25）, Neiguan（PC6）, Liangqiu（ST34）, Yanglinquan（GB34）, Zusanli（ST36）and Taichong（LR3）.All the acupoints will be localized according to the Nomenclature and Location of Acupuncture Points of the People's Republic of China. During the acupuncture treatment, the participants will be in supine position. After 75% alcohol pads sterilizing the skin around the acupoints routinely, the acupuncturists will use sterile disposable steel needles (0.3 mm×40 mm; Huatuo Brand, Suzhou Medical Appliance, China) to insert into the acupoints above. The acupoints will be inserted vertically at 13-40 mm with the manipulation of steady small lifting, thrusting, and twirling 3 times to induce a sensation of de qi (sourness, numbness, and heaviness).
Study NCT00597350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Trigonella foenum-graecum (fenugreek)
Description: 2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
Study NCT01209039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Multiple daily doses of GSK1144814 for 28 days
Study NCT01209039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Multiple daily doses of GSK1144814 for 14 days
Study NCT01527994 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant 125 mg oral tablets
Study NCT03215706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified day
Study NCT01980940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel
Description: Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
Study NCT01423370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1023
Description: 5g oral once daily
Study NCT01527994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo oral pill- inactive compound
Study NCT03048682 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley catheter - Early Voiding Trial
Description: All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator.
Study NCT03048682 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley catheter - Late Voiding Trial
Description: All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.~Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice
Study NCT01209039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1144814
Description: Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
Study NCT01423370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1023
Description: 5g oral twice a day
Study NCT01423370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1023
Description: 10g oral once daily
Study NCT01423370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cialis
Description: 5mg oral once daily
Study NCT01423370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT04262570 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)
Description: Non-invasive transcutaneous imaging of molecular muscle components
Study NCT04262570 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral Optoacoustic Tomography (MSOT) and Magnetic Resonance Imaging (MRI)
Description: Non-invasive transcutaneous imaging of molecular muscle components
Study NCT00600457 — intervention group
Intervention type: DEVICE
Intervention: Polyurethane Film
Description: The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
Study NCT01682200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProOxy
Description: Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
Study NCT02021760 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary Percutanous Coronary Intervention is performed in both Groups.
Study NCT02021760 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Primary Percutaneous Coronary Intervention
Description: Primary Percutanous Coronary Intervention is performed in both Groups.
Study NCT01477619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasimelteon
Description: 20mg single dose on Day 1
Study NCT03215706 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day
Study NCT03215706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Specified dose on specified day
Study NCT03215706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Specified dose on specified day
Study NCT03215706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Specified dose on specified day
Study NCT03215706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Specified dose on specified day
Study NCT02517411 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: The standard care of stable COPD is based on long-acting bronchodilators (LABD).
Study NCT02517411 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy added to standard care
Description: The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
Study NCT04092985 — intervention group
Intervention type: DEVICE
Intervention: iECG recording
Description: iECG tracings will be recorded simultaneously, starting and ending at the same time as the standard 12-lead ECG, using the built-in sensors of a smart watch (Apple Watch Series 4) with the ECG application
Study NCT03215706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Specified dose on specified day
Study NCT03215706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Specified dose on specified day
Study NCT03215706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Specified dose on specified day
Study NCT03215706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Specified dose on specified day
Study NCT02058927 — intervention group
Intervention type: DRUG
Intervention: Measles vaccine
Description: measles revaccination administered at 12 months from start of ART
Study NCT02811458 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive-Behavioral Therapy
Description: Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
Study NCT03699852 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Membracel and LED photobiomodulation
Description: Participants were positioned so that the skin graft donor area was accessible. A light-emitting diode (LED) plate was covered with sterile transparent and waterproof film to prevent contamination when in contact with the donor area. The application was in contact, with full coverage of the surgical wound and was irradiated with radiant exposure of 1.53J / cm2 and irradiance of 2.55 mW / cm2 for 10 minutes. It is worth mentioning that the LED plate was applied in direct contact with the skin graft donor area in the immediate postoperative period and on the primary cover used (Membracel®) on the 1st, 3rd, 5th and 7th postoperative days. Coverage remained until spontaneous departure. The researcher and the participants used specific goggles for this procedure.
Study NCT03699852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Membracel
Description: This group did not receive LED application, remaining with the skin donor area covered by Membracel® and were evaluated under the same conditions.
Study NCT00878540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirtazapine
Description: 30 mg mirtazapine once daily for 7 days
Study NCT00430521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 1
Description: 2 or 3 doses, intramuscular injection, at different time points.
Study NCT02652832 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non invasive brain stimulation
Description: non invasive brain stimulation
Study NCT02652832 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: non invasive brain stimulation
Description: non invasive brain stimulation
Study NCT03532191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PrEP Optimization Intervention (PrEP-OI)
Description: PrEP-Rx + PrEP Coordinator
Study NCT01212757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20mg
Description: Apremilast 20 mg twice daily, orally
Study NCT01212757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30mg
Description: Apremilast 30 mg twice daily, orally
Study NCT01212757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 20 mg Apremilast
Description: Placebo + 20 mg Apremilast
Study NCT01212757 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + 30 mg Apremilast
Description: Placebo + 30 mg Apremilast
Study NCT03714750 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DK crush
Description: revascularization of true coronary bifurcation stenosis in DK crush technique
Study NCT03714750 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reverse TAP
Description: revascularization of true coronary bifurcation stenosis in Reverse TAP technique
Study NCT01357044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Extracts of Punica granatum and Alpinia galanga
Description: Tablets, two in the morning and two in the evening
Study NCT01357044 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, two in the morning and two in the evening
Study NCT04010643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: online cognitive behavioural therapy
Description: oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey \& O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
Study NCT04010643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online cognitive behavioural therapy
Description: oCBT: MoodGym is a 5-week oCBT program developed by the Centre for Mental Health Research at the Australian National University. This program has been shown to be clinically effective at reducing mood symptoms in depression studies (see meta-analytical review of Twomey \& O'Reilly, 2017). MoodGym consists of a number of interactive modules to be completed sequentially and including work on own feelings, thoughts, methods to change dysfunctional thinking patterns, de-stressing, and relaxation. Each module is followed by an associated practical homework, while a personalised workbook allows the participant to track their mood profile and progress throughout the modules.
Study NCT04010643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online neurocognitive remediation therapy
Description: NCRT involves the behavioural application of structured exercises targeting neurocognitive processes by mobilising neuroplasticity that is the brain's ability to adjust its function in response to environmental change. Computerised NCRT has demonstrated efficacy to improve attention, working memory and global functioning in depression (Motter et al., 2016; Semkovska et al., 2015). NCRT is delivered through the Cognifit online programme. The Cognifit modules were selected as targeting remediation of neurocognitive domains known to be impaired in depression, i.e. selective and divided attention, visual and verbal working memory, and everyday planning (Hammar and Ardal, 2009; Semkovska et al., 2019).
Study NCT01419717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection every 4 weeks (Q4W)
Study NCT02857283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Participants will be exposed to a concentration of ozone for 6.5 hours at a concentration that varies 0.06 to 0.08
Study NCT00430521 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine (GSK1119711A)-formulation 2
Description: 2 or 3 doses, intramuscular injection, at different time points.
Study NCT01560546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone
Description: 50 mg/dose/day for 24 weeks
Study NCT01560546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo on the skin for 24 weeks
Study NCT01423617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zenoctil
Description: 3 tablets 2 times daily
Study NCT01423617 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 tablets 2 times daily
Study NCT02704728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thetanix
Description: Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
Study NCT02704728 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
Study NCT02232672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Choline PET/CT and MeAIB PET/CT
Description: Choline PET/CT and MeAIB PET/CT
Study NCT02370849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nimotuzumab
Description: nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
Study NCT00108628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery Rehearsal
Description: IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
Study NCT00108628 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep and Nightmare Management
Description: This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
Study NCT03527680 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Description: daily one capsule containing 1.6\*107 CFU of Lactobacillus Rhamnosus prepared by Tabriz Nutrition Research Center from yogurt and cheese of different farms located in the suburbs Heris, after meal for 28 days
Study NCT03527680 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: daily one capsule of placebo
Study NCT03068845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon angioplasty (DEBA)
Description: DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin.
Study NCT03068845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Balloon Angioplasty (CBA)
Description: CBA will be performed for the target lesion for subjects allocated to the active comparator arm.~If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.~High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).~All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin.
Study NCT02339415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban 30mg daily
Study NCT02339415 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Study NCT03259191 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: anti-reflux mucosectomy
Description: Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
Study NCT03856606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting without exercise
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
Study NCT03856606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged sitting with interval exercise
Description: Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo a prolonged sit which with will be broken up every hour on the hour by a small bout of interval exercise. Day 4 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.